Nationally, newborn screening programs use 17-hydroxyprogesterone (17-OHP) as the biomarker to detect the rare but potentially fatal inherited disease, congenital adrenal hyperplasia. However, this biomarker is highly variable, with a high false-positive rate of detection, particularly in neonates born preterm. Several studies have examined various clinical and genetic factors to explain the variability of 17-OHP in preterm infants. The purpose of this study was to replicate previous clinical and genetic associations with 17-OHP in a well-characterized cohort of 762 preterm infants. We replicated previous fi ndings that respiratory distress syndrome (p = 2 × 10 − 3 ) is associated with higher 17-OHP. Higher 17-OHP and false positives were signifi cantly associated with lower gestational age and birth weight, as previously reported. Incorporating gestational age and birth weight together decreases the falsepositive rate.
Introduction
Congenital adrenal hyperplasia (CAH; OMIM 201910) is an inherited autosomal recessive disorder of cortisol biosynthesis occurring in approximately 1 of every 10,000 -15,000 live births (1, 2) . 17-Hydroxyprogesterone (17-OHP) is the biomarker used in newborn screening programs nationwide to screen for CAH and elevated levels of 17-OHP identify infants that need further testing. However, 17-OHP is highly variable and has a higher false-positive rate, particularly in preterm and low-birth-weight neonates (2, 3) . It is well known that preterm and sick term infants often have higher 17-OHP levels than healthy term infants even though they are not affected by CAH (2, 4) . The underlying mechanism for this observation is unclear and has often been largely attributed to fetal stress (4) . Several studies have examined neonatal illnesses, such as respiratory distress syndrome (RDS) and maternal conditions, such as preeclampsia and observed higher levels of 17-OHP in these infants (5) . However, these associations have not replicated in several studies, and healthy preterm infants still have much higher 17-OHP than their term counterparts (4, 6) . Some explanations include immature adrenal function, immature kidney function, and higher levels of adrenocorticotropic hormone (7 -9) .
Genetic factors may also infl uence the variability of 17-OHP concentrations. Of particular interest are genes involved in the steroidogenic pathway, in particular cytochrome P450 genes CYP21A2 , CYP11B1 , and CYP17A1 that harbor rare variants responsible for different forms of CAH. Several studies have identifi ed polymorphisms in CYP21 that infl uence 17-OHP levels in patients with nonclassical CAH (10, 11) . Another study observed an association between the glucocorticoid receptor gene ( NR3C1 ) and 17-OHP levels; however, this was not replicated in a study of 1000 random samples from routine newborn screening (12) . It is feasible, but has not been previously investigated, that common polymorphisms in CYP21 and related genes infl uence the variability of 17-OHP in preterm infants that do not have CAH.
The variability of 17-OHP in preterm infants leads to a signifi cantly increased false-positive rate in this population (3) . Many states have taken measures, such as having birth weight or gestational age specifi c thresholds, to reduce the false-positive rate in preterm infants. However, it is observed that there is still a high false-positive rate in preterm and lowbirth-weight infants even with this adjustment (3) . Secondtier methods, such as liquid chromatography-tandem mass spectrometry (LC-MS/MS) have been proposed to lower the false-positive rate of CAH testing (13) ; however, due to the analytical time required to run this method, it is not feasible as a fi rst-tier screen. In 2009, the Clinical and Laboratory Standards Institute recommended that all preterm and lowbirth-weight infants be screened at birth, 48 -72 h after birth, and at 28 days of life (14) . This delays fi nal reporting and signifi cantly increases the cost of screening. Examining clinical and genetic infl uences on variation in 17-OHP will lead to a greater understanding of steroidogenesis in preterm newborns and result in better screening methods for CAH. We investigated this in preterm infants utilizing data from the Iowa Neonatal Metabolic Screening Program.
Materials and methods

Study population
This is a retrospective analysis of data collected as part of a prospective cohort for studying the epidemiology and genetics of preterm birth (15, 16) . Study samples were collected at the University of Iowa Hospitals and Clinics in Iowa City, IA, USA. Signed informed consent (IRB200506792) was obtained from all families for enrollment. DNA was extracted from cord blood or buccal swabs collected from infants and venous blood, saliva samples, or buccal swabs collected from parents and other relatives between 2000 and 2009. Existing data collected by an interview with the mother, medical chart review, or both was mined for 54 clinical and demographic factors; completeness of the data varied across subjects (Supplemental Table 1 ). Gestational age and birth weight were obtained from the medical record, if available; otherwise, information reported on the newborn screen card was used. 17-OHP measurements were obtained from the State Hygienic Laboratory using the Clinical Laboratory Improvement Amendments. Quantifi cation of 17-OHP was determined with a solid-phase, time-resolved fl uoroimmunoassay from dried newborn blood spots using PerkinElmer ' s DELFIA ® or AutoDELFIA ® platform (Waltham, MA, USA). Inclusion criteria included specimen collection between 24 h and 72 h after birth, no blood product transfusion, and birth before 37 weeks gestation. There were genotype and phenotype data on 148 sets of multiples (twins or triplets) available for this study; the infant with the most complete information with respect to clinical and genetic data was chosen from each set for inclusion in this analysis. A total of 762 preterm infants met the inclusion criteria for this study. Single-nucleotide polymorphisms (SNPs) from candidate genes within the steroidogenic pathway and related CYP P450 genes were previously genotyped as part of a study examining genetic association with preterm birth and complications (unpublished work). CYP P450 genes encode for a diverse group of enzymes that have function in lipid and steroid metabolism, vitamin D regulation, and drug metabolism. Additional genotyping was performed in CYP11B1 , CYP17A1 , CYP21A2 , and NR3C1 to saturate genes previously shown to associate with CAH or 17-OHP. All genotyping was completed using the Applied Biosystems (Foster City, CA, USA) TaqMan ® chemistry under standard conditions. A total of 44 SNPs were examined in this study (Supplemental Table 2 . Genetic analysis was limited to Caucasian infants without congenital or chromosomal abnormalities to avoid potential confounding caused by population stratifi cation and structural or chromosomal aberrations. A total of 393 infants had genotype data on some or all of the SNPs. Parental and/or sibling genotypes were available in most cases and were included in the family-based analysis.
Statistical analysis
Analysis of variance (ANOVA) was performed to identify clinical and genetic associations with 17-OHP levels. 17-OHP was transformed using the Box Cox method of transformation to normalize measurement values. Standardized residuals were examined for outliers and measurements that were lower than -3.5 or >3.5 were removed. Statistical modeling was performed to determine the most appropriate method of analysis and to identify potentially confounding covariates. Birth weight, gestational age, year of sample collection, and major change in the assay lot of 17-OHP were included in models presented; differences in results between models and methods are indicated in Supplemental Table 3 . A Bonferroni signifi cance threshold of p < 9 × 10 − 4 (0.05/54 tests) was used to correct for multiple testing. Stata version 10.1 (Stata Corporation, College Station, TX, USA) was used for all analyses. All infants with borderline (n = 44) and presumptive positive (n = 30) CAH test results were normal on subsequent screens. We did not have the ability in our population to identify missed cases of CAH nor were we able to propose hypothetical thresholds based on our data, as we had no confi rmed cases of CAH in our study. Borderline and presumptive positive results are determined by the threshold of 17-OHP concentration with higher concentrations being diagnosed as presumptive positive; however, clinically borderline and presumptive positive test results were followed up in the same manner, with each infant receiving a second screening test. Therefore, we combined presumptive positive and borderline test results into one false-positive test result category. We compared false-positive test results with negative results for factors associated with 17-OHP concentrations using Fisher exact tests. Analysis broken down into subgroups is provided in Supplemental Table 4 .
Genotypes were tested for deviations from Hardy-Weinberg equilibrium (HWE) using Fisher exact tests. Genotype data were analyzed using ANOVA, adjusting for year of sample collection, major change in the 17-OHP assay, gestational age, and birth weight. Additive, dominant, and recessive models were applied. A Bonferroni signifi cance threshold of p < 3.8 × 10 − 4 (0.05/132 tests) was used to correct for multiple testing. Global haplotype analysis using permutation testing to obtain p-values was performed within each gene for blocks of 2, 3, and 4 SNPs using the publicly available software program PLINK (http://pngu.mgh.harvard.edu/purcell/plink/) (17) . Quantitative transmission disequilibrium tests, adjusting for assay change, year, gestational age, and birth weight, were also performed on parent-infant trios including any genotyped siblings to determine if the transmission of parental alleles to the offspring was associated with transformed 17-OHP concentrations (18) . Permutation tests were used to correct for the non-linear distribution of 17-OHP.
Results
Clinical results
Gestational age and birth weight were the strongest contributors to variation in 17-OHP concentration (Figure 1 A  and B) . Signifi cantly more positive test results (p = 1.1 × 10 − 4 ) were observed in infants at the upper ( > 2500 g) and lower ( < 1250 g) extremes of birth weight (Table 1 ) , whereas no signifi cant (p = 0.16) differences were observed by gestational age. There was also a strong association between weight for gestational age (WGA) and 17-OHP (p = 8.3 × 10 − 4 ) ( Figure  1C ). Subsequent analysis identifi ed that this effect was driven by the large for gestational age (LGA) group (p = 9.1 × 10 − 4 ) not the small for gestational age (SGA) group (p = 0.11).
LGA and SGA infants had fewer false-positive CAH test results than average for gestational age (AGA) infants (p = 2.3 × 10 ). No other clinical or demographic variable was associated with 17-OHP concentrations in our study after correction for multiple testing (p < 9 × 10 − 4 ). We observed marginally higher concentrations of 17-OHP associated with RDS, and this concentration difference resulted in more false-positive test results in infants with RDS (p = 0.01) (Figure 2 and Table 1 ).
Genetic results
CYP24A1 (rs2248359 and rs927650), CYP27A1 (rs4674338), and CYP21A2 (rs12525076) were associated with 17-OHP concentrations; however, none reached signifi cance after correction for multiple testing (p < 3.8 × 10 − 4 ). Infants with either homozygous genotype (TT or CC) at rs2248359 in CYP24A1 had higher 17-OHP levels compared with those with the heterozygous genotype (p = 0.01), and this correlated with signifi cantly more false-positive CAH test results ( Figure  3 A and Table 2 ). Infants with the CC genotype at rs927650 in CYP24A1 had higher 17-OHP compared with those with the CT or TT genotypes (p = 0.03), and this correlated with more false-positive CAH test results ( Figure 3B and Table  2 ). Genotypes at rs4674338 in CYP27A1 and rs12525076 in CYP21A2 associated with 17-OHP concentrations; however, these were not signifi cantly associated with false-positive CAH test results (Table 2 and Supplemental Table 2 ). There were no signifi cant haplotype associations with 17-OHP, nor LGA SGA Figure 1 Associations between 17-OHP and (A) birth weight, (B) gestational age, and (C) WGA. The signifi cance (p-value) is presented, adjusted for year of collection and change in the 17-OHP assay. were any SNPs signifi cantly associated with 17-OHP in the family-based analyses (Supplemental Tables 2 and 5 ).
Discussion
17-OHP is highly variable, particularly in preterm infants, which results in a high false-positive rate for CAH in this group. However, the variability of this biomarker in preterm infants has been poorly characterized. Many studies attribute elevated 17-OHP in preterm infants to fetal stress; however, very little is known about the impact of maternal conditions, environmental infl uence, infant outcomes, and genetic factors on the steroid profi les of premature neonates. We evaluated an extensive list of maternal and fetal conditions and characteristics for associations with 17-OHP to determine if these factors were not only important in understanding steroidogenesis in preterm infants but also for identifying factors that could potentially improve the specifi city of CAH testing. This is of particular importance in the preterm population, as these infants and their parents are already under a great deal of stress due to the complications and treatments of prematurity. Gestational age and birth weight were major contributors to the variation in 17-OHP concentrations in our preterm on newborn screening (5, 20) . We found that SGA newborns had no false positives reported; however, we were unable to examine the impact of this on the false-negative rate because we were unable to determine if cases of CAH were missed in our population. We were also not able to propose hypothetical thresholds based on our data, as we had no confi rmed cases of CAH in our study. Further investigation in larger studies that have true CAH cases and potentially missed CAH cases is needed to determine if thresholds based on WGA more adequately control for the false-positive rate of 17-OHP testing while not increasing the false-negative rate.
We replicated previous studies that observed RDS results in higher concentrations of 17-OHP (5) . Previously, it was concluded that this result was a marker for infant sickness and due solely to the association with birth weight (5) . However, we observe that RDS is associated independent of birth weight and results in more false-positive CAH test results. We also did not fi nd any other associations between other infant illnesses and 17-OHP when controlling for birth weight and gestational age. Therefore, these data suggest that unlike fetal illnesses 17-OHP levels are particularly sensitive to RDS; further investigation on the mechanism of this phenomenon is warranted.
We identifi ed novel genetic associations between CYP21A2 , CYP24A1 , and CYP27A1 and 17-OHP levels. Rare mutations in the CYP21A2 gene cause the most common form of CAH. Our association was between a common intronic variant (allele frequency of 36 % ) in CYP21A2 ; however, the functional signifi cance of this fi nding is unclear. CYP24A1 and CYP27A1 are vitamin D metabolism-related genes, and studies show a link between delayed bone maturation and CAH due to treatment with glucocorticoids (21) . However, the uncertain biological and weak statistical evidence for the involvement of genetic variants in the regulation of 17-OHP levels makes additional replication studies necessary. Identifying genetic associations in a population of healthy term infants is also important for determining the impact of gene-environment interactions on 17-OHP concentrations and is currently underway.
These fi ndings are important for guiding future studies of the clinical impact on 17-OHP concentrations as well as determining factors that may potentially infl uence population. In Iowa, four birth weight categories ( < 1250 g, 1250 -1749.9, 1750 -2249.9, and ≥ 2250 g) are used to adjust levels of 17-OHP when determining CAH test results. We observed that even with these adjusted thresholds preterm infants at the high ( > 2250 g) and low ( < 1250 g) extremes of birth weight are more likely to receive false-positive results. This indicates that, in preterm infants, adjusting for birth weight with the current thresholds is not adequately controlling the false-positive rate and additional thresholds should be evaluated, particularly at the extremes of birth weight in preterm infants. We found that incorporating gestational age and birth weight into three categories, SGA, LGA, and AGA, for gestational age resulted in fewer false positives at the extremes (SGA and LGA). This is in line with other studies that have suggested that including gestational age in addition to birth weight when determining the diagnostic thresholds for 17-OHP is important (19) . Smaller studies have also demonstrated that SGA infants have lower 17-OHP than term infants, which is likely due to a decreased capacity for steroidogenesis; none of these studies evaluated the effect false-positive CAH results. Understanding the interactions between key environmental and genetic factors on 17-OHP will allow for a more accurate newborn screening test. These fi ndings provide important insights into the steroid profi les of preterm neonates, which is particularly important because this group of infants has a high rate of infant morbidity and mortality. Further investigation of genes within the steroidogenic pathway will deepen the understanding of steroidogenic pathway dynamics and contributors to 17-OHP variability in newborns, leading to improvements in the interpretation of screening data.
